Hi all,
just finished reading this article about FDA`s plans in the space for rare disease. In my opinion all points raised in this article, NEUREN already has a strategy in place, which is very much in line of what the FDA intends to do.
Happy reading
https://www.marketwatch.com/story/new-fda-program-could-boost-drug-development-for-rare-diseases-11644935201
Focus now on NNZ2591, page-58
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |